Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Julie Chao and Lee Chao.
Julie Chao
Connection Strength
18.680
Lee Chao
  1. Protective Role of Endogenous Kallistatin in Vascular Injury and Senescence by Inhibiting Oxidative Stress and Inflammation. Oxid Med Cell Longev. 2018; 2018:4138560.
    View in: PubMed
    Score: 0.661
  2. Opposing Effects of Oxygen Regulation on Kallistatin Expression: Kallistatin as a Novel Mediator of Oxygen-Induced HIF-1-eNOS-NO Pathway. Oxid Med Cell Longev. 2017; 2017:5262958.
    View in: PubMed
    Score: 0.618
  3. Kallistatin: double-edged role in angiogenesis, apoptosis and oxidative stress. Biol Chem. 2017 11 27; 398(12):1309-1317.
    View in: PubMed
    Score: 0.616
  4. Role of Kallistatin Treatment in Aging and Cancer by Modulating miR-34a and miR-21 Expression. Oxid Med Cell Longev. 2017; 2017:5025610.
    View in: PubMed
    Score: 0.599
  5. Kallistatin suppresses cancer development by multi-factorial actions. Crit Rev Oncol Hematol. 2017 May; 113:71-78.
    View in: PubMed
    Score: 0.587
  6. Protective Role of Kallistatin in Vascular and Organ Injury. Hypertension. 2016 09; 68(3):533-41.
    View in: PubMed
    Score: 0.561
  7. Kallikrein-kinin in stem cell therapy. World J Stem Cells. 2014 Sep 26; 6(4):448-57.
    View in: PubMed
    Score: 0.495
  8. Tissue kallikrein-kinin therapy in hypertension and organ damage. Prog Drug Res. 2014; 69:37-57.
    View in: PubMed
    Score: 0.470
  9. Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing. Biol Chem. 2010 Apr; 391(4):345-55.
    View in: PubMed
    Score: 0.362
  10. Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation. Hypertension. 2008 Oct; 52(4):715-20.
    View in: PubMed
    Score: 0.325
  11. Kinin infusion prevents renal inflammation, apoptosis, and fibrosis via inhibition of oxidative stress and mitogen-activated protein kinase activity. Hypertension. 2007 Mar; 49(3):490-7.
    View in: PubMed
    Score: 0.290
  12. Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. Hum Gene Ther. 2006 Dec; 17(12):1201-13.
    View in: PubMed
    Score: 0.288
  13. The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction. Biol Chem. 2006 Jun; 387(6):665-75.
    View in: PubMed
    Score: 0.278
  14. Experimental therapy with tissue kallikrein against cerebral ischemia. Front Biosci. 2006 May 01; 11:1323-7.
    View in: PubMed
    Score: 0.276
  15. Kallikrein-kinin in stroke, cardiovascular and renal disease. Exp Physiol. 2005 May; 90(3):291-8.
    View in: PubMed
    Score: 0.253
  16. Adenovirus-mediated gene transfer for cardiovascular and renal diseases. Methods Enzymol. 2002; 346:247-63.
    View in: PubMed
    Score: 0.205
  17. Human adrenomedullin gene delivery protects against cardiovascular remodeling and renal injury. Peptides. 2001 Nov; 22(11):1731-7.
    View in: PubMed
    Score: 0.202
  18. Novel roles of kallistatin, a specific tissue kallikrein inhibitor, in vascular remodeling. Biol Chem. 2001 Jan; 382(1):15-21.
    View in: PubMed
    Score: 0.191
  19. Gene therapy for hypertension: a review of potential targets. BioDrugs. 1999 Jan; 11(1):43-53.
    View in: PubMed
    Score: 0.166
  20. Reduced Plasma Kallistatin Is Associated With the Severity of Coronary Artery Disease, and Kallistatin Treatment Attenuates Atherosclerotic Plaque Formation in Mice. J Am Heart Assoc. 2018 11 06; 7(21):e009562.
    View in: PubMed
    Score: 0.164
  21. Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats. Kidney Int. 1998 Oct; 54(4):1250-60.
    View in: PubMed
    Score: 0.163
  22. Kallistatin attenuates endothelial senescence by modulating Let-7g-mediated miR-34a-SIRT1-eNOS pathway. J Cell Mol Med. 2018 09; 22(9):4387-4398.
    View in: PubMed
    Score: 0.161
  23. Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats. Hum Gene Ther. 1998 Jan 01; 9(1):21-31.
    View in: PubMed
    Score: 0.155
  24. Kallistatin in blood pressure regulation transgenic and somatic gene delivery studies. Trends Cardiovasc Med. 1997 Nov; 7(8):307-11.
    View in: PubMed
    Score: 0.153
  25. New experimental evidence for a role of tissue kallikrein in hypertension. Nephrol Dial Transplant. 1997 Aug; 12(8):1569-74.
    View in: PubMed
    Score: 0.151
  26. Kallistatin is a potent new vasodilator. J Clin Invest. 1997 Jul 01; 100(1):11-7.
    View in: PubMed
    Score: 0.150
  27. Kallikrein gene therapy: a new strategy for hypertensive diseases. Immunopharmacology. 1997 Jun; 36(2-3):229-36.
    View in: PubMed
    Score: 0.149
  28. Kallikrein gene therapy in newborn and adult hypertensive rats. Can J Physiol Pharmacol. 1997 Jun; 75(6):750-6.
    View in: PubMed
    Score: 0.149
  29. Experimental kallikrein gene therapy in hypertension, cardiovascular and renal diseases. Pharmacol Res. 1997 Jun; 35(6):517-22.
    View in: PubMed
    Score: 0.149
  30. Kallistatin reduces vascular senescence and aging by regulating microRNA-34a-SIRT1 pathway. Aging Cell. 2017 08; 16(4):837-846.
    View in: PubMed
    Score: 0.149
  31. Kallistatin, a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease. J Lab Clin Med. 1996 Jun; 127(6):612-20.
    View in: PubMed
    Score: 0.139
  32. Systemic and portal vein delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hum Gene Ther. 1996 May 20; 7(8):901-11.
    View in: PubMed
    Score: 0.139
  33. Tissue kallikrein inhibitors in mammals. Immunopharmacology. 1996 May; 32(1-3):67-72.
    View in: PubMed
    Score: 0.138
  34. Functional analysis of human tissue kallikrein in transgenic mouse models. Hypertension. 1996 Mar; 27(3 Pt 2):491-4.
    View in: PubMed
    Score: 0.137
  35. Kallistatin induces breast cancer cell apoptosis and autophagy by modulating Wnt signaling and microRNA synthesis. Exp Cell Res. 2016 Jan 15; 340(2):305-14.
    View in: PubMed
    Score: 0.135
  36. Biochemistry, regulation and potential function of kallistatin. Biol Chem Hoppe Seyler. 1995 Dec; 376(12):705-13.
    View in: PubMed
    Score: 0.134
  37. Kallistatin inhibits TGF-?-induced endothelial-mesenchymal transition by differential regulation of microRNA-21 and eNOS expression. Exp Cell Res. 2015 Sep 10; 337(1):103-10.
    View in: PubMed
    Score: 0.130
  38. Kallistatin treatment attenuates lethality and organ injury in mouse models of established sepsis. Crit Care. 2015 May 01; 19:200.
    View in: PubMed
    Score: 0.129
  39. Novel role of kallistatin in vascular repair by promoting mobility, viability, and function of endothelial progenitor cells. J Am Heart Assoc. 2014 Sep 18; 3(5):e001194.
    View in: PubMed
    Score: 0.123
  40. Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis. Immunology. 2014 Jun; 142(2):216-26.
    View in: PubMed
    Score: 0.121
  41. Regulation of kininogen gene expression and localization in the lung after monocrotaline-induced pulmonary hypertension in rats. Proc Soc Exp Biol Med. 1993 Jun; 203(2):243-50.
    View in: PubMed
    Score: 0.113
  42. Tissue kallikrein-modified mesenchymal stem cells provide enhanced protection against ischemic cardiac injury after myocardial infarction. Circ J. 2013; 77(8):2134-44.
    View in: PubMed
    Score: 0.113
  43. Kallistatin antagonizes Wnt/?-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6. Mol Cell Biochem. 2013 Jul; 379(1-2):295-301.
    View in: PubMed
    Score: 0.112
  44. Tissue kallikrein is related to the severity of coronary artery disease. Clin Chim Acta. 2013 Aug 23; 423:90-8.
    View in: PubMed
    Score: 0.112
  45. Tissue kallikrein-modified human endothelial progenitor cell implantation improves cardiac function via enhanced activation of akt and increased angiogenesis. Lab Invest. 2013 May; 93(5):577-91.
    View in: PubMed
    Score: 0.111
  46. Screening of complementary DNA library using radiolabeled antigen. Methods Enzymol. 1993; 217:325-35.
    View in: PubMed
    Score: 0.110
  47. Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling. Am J Physiol Renal Physiol. 2012 Oct 15; 303(8):F1230-8.
    View in: PubMed
    Score: 0.106
  48. Tissue kallikrein promotes cardiac neovascularization by enhancing endothelial progenitor cell functional capacity. Hum Gene Ther. 2012 Aug; 23(8):859-70.
    View in: PubMed
    Score: 0.105
  49. Expression of kallikrein-binding protein and alpha 1-antitrypsin genes in response to sex hormones, growth, inflammation and hypertension. Agents Actions Suppl. 1992; 38 ( Pt 1):174-81.
    View in: PubMed
    Score: 0.102
  50. Tissue kallikrein-binding protein is a serpin. I. Purification, characterization, and distribution in normotensive and spontaneously hypertensive rats. J Biol Chem. 1990 Sep 25; 265(27):16394-401.
    View in: PubMed
    Score: 0.094
  51. Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling. Am J Physiol Heart Circ Physiol. 2010 Nov; 299(5):H1419-27.
    View in: PubMed
    Score: 0.093
  52. Tissue kallikrein promotes prostate cancer cell migration and invasion via a protease-activated receptor-1-dependent signaling pathway. Biol Chem. 2010 Jul; 391(7):803-12.
    View in: PubMed
    Score: 0.092
  53. Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation. Hypertension. 2010 Aug; 56(2):260-7.
    View in: PubMed
    Score: 0.092
  54. Blockade of endogenous tissue kallikrein aggravates renal injury by enhancing oxidative stress and inhibiting matrix degradation. Am J Physiol Renal Physiol. 2010 Apr; 298(4):F1033-40.
    View in: PubMed
    Score: 0.089
  55. Pivotal role of JNK-dependent FOXO1 activation in downregulation of kallistatin expression by oxidative stress. Am J Physiol Heart Circ Physiol. 2010 Mar; 298(3):H1048-54.
    View in: PubMed
    Score: 0.089
  56. Kruppel-like factor 4 is a novel mediator of Kallistatin in inhibiting endothelial inflammation via increased endothelial nitric-oxide synthase expression. J Biol Chem. 2009 Dec 18; 284(51):35471-8.
    View in: PubMed
    Score: 0.089
  57. A novel signaling pathway of tissue kallikrein in promoting keratinocyte migration: activation of proteinase-activated receptor 1 and epidermal growth factor receptor. Exp Cell Res. 2010 Feb 01; 316(3):376-89.
    View in: PubMed
    Score: 0.088
  58. Intermedin is a new angiogenic growth factor. Am J Physiol Heart Circ Physiol. 2009 Sep; 297(3):H1040-7.
    View in: PubMed
    Score: 0.086
  59. Structural analysis of a rat renal kallikrein gene. Adv Exp Med Biol. 1989; 247A:73-80.
    View in: PubMed
    Score: 0.083
  60. Sex dimorphism and estrogen regulation of kininogens in rat serum, adrenal gland and kidney. Adv Exp Med Biol. 1989; 247B:297-303.
    View in: PubMed
    Score: 0.083
  61. Intermedin ameliorates vascular and renal injury by inhibition of oxidative stress. Am J Physiol Renal Physiol. 2008 Dec; 295(6):F1735-43.
    View in: PubMed
    Score: 0.082
  62. Role of kallistatin in prevention of cardiac remodeling after chronic myocardial infarction. Lab Invest. 2008 Nov; 88(11):1157-66.
    View in: PubMed
    Score: 0.081
  63. Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt-glycogen synthase kinase-3beta pathway. Cardiovasc Res. 2008 Dec 01; 80(3):354-64.
    View in: PubMed
    Score: 0.081
  64. Kallikrein-modified mesenchymal stem cell implantation provides enhanced protection against acute ischemic kidney injury by inhibiting apoptosis and inflammation. Hum Gene Ther. 2008 Aug; 19(8):807-19.
    View in: PubMed
    Score: 0.081
  65. A major difference of kallikrein-binding protein in spontaneously hypertensive versus normotensive rats. J Hypertens. 1988 Jul; 6(7):551-7.
    View in: PubMed
    Score: 0.080
  66. Tissue kallikrein and kinin infusion promotes neovascularization in limb ischemia. Biol Chem. 2008 Jun; 389(6):725-30.
    View in: PubMed
    Score: 0.080
  67. Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension. 2008 May; 51(5):1358-65.
    View in: PubMed
    Score: 0.079
  68. Tissue distribution and kininogen gene expression after acute-phase inflammation. Biochim Biophys Acta. 1988 Mar 17; 964(3):329-39.
    View in: PubMed
    Score: 0.079
  69. Circulating autoantibodies to mammalian tissue kallikreins. Proc Soc Exp Biol Med. 1988 Mar; 187(3):320-6.
    View in: PubMed
    Score: 0.078
  70. Role of tissue kallikrein in prevention and recovery of gentamicin-induced renal injury. Toxicol Sci. 2008 Apr; 102(2):433-43.
    View in: PubMed
    Score: 0.078
  71. Identification and expression of kallikrein gene family in rat submandibular and prostate glands using monoclonal antibodies as specific probes. Biochim Biophys Acta. 1987 Dec 08; 910(3):233-9.
    View in: PubMed
    Score: 0.077
  72. Nitric oxide mediates cardiac protection of tissue kallikrein by reducing inflammation and ventricular remodeling after myocardial ischemia/reperfusion. Life Sci. 2008 Jan 16; 82(3-4):156-65.
    View in: PubMed
    Score: 0.077
  73. Upregulation of kallistatin expression in rheumatoid joints. J Rheumatol. 2007 Nov; 34(11):2171-6.
    View in: PubMed
    Score: 0.076
  74. Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction. J Card Fail. 2007 Sep; 13(7):588-96.
    View in: PubMed
    Score: 0.076
  75. Differential role of kinin B1 and B2 receptors in ischemia-induced apoptosis and ventricular remodeling. Peptides. 2007 Jul; 28(7):1383-9.
    View in: PubMed
    Score: 0.074
  76. Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction. Regul Pept. 2007 Apr 05; 140(1-2):12-20.
    View in: PubMed
    Score: 0.072
  77. Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation. Cardiovasc Res. 2007 Jan 01; 73(1):130-42.
    View in: PubMed
    Score: 0.071
  78. Reversal of renal fibrosis, inflammation, and glomerular hypertrophy by kallikrein gene delivery. Hum Gene Ther. 2006 May; 17(5):545-55.
    View in: PubMed
    Score: 0.069
  79. Postischemic brain injury is exacerbated in mice lacking the kinin B2 receptor. Hypertension. 2006 Apr; 47(4):752-61.
    View in: PubMed
    Score: 0.068
  80. Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. Hum Gene Ther. 2006 Feb; 17(2):206-19.
    View in: PubMed
    Score: 0.068
  81. Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. Nephrol Dial Transplant. 2006 Mar; 21(3):624-33.
    View in: PubMed
    Score: 0.068
  82. Postischemic infusion of adrenomedullin protects against ischemic stroke by inhibiting apoptosis and promoting angiogenesis. Exp Neurol. 2006 Feb; 197(2):521-30.
    View in: PubMed
    Score: 0.067
  83. Kallikrein gene transfer reduces renal fibrosis, hypertrophy, and proliferation in DOCA-salt hypertensive rats. Am J Physiol Renal Physiol. 2005 Sep; 289(3):F622-31.
    View in: PubMed
    Score: 0.065
  84. Kallikrein gene delivery improves serum glucose and lipid profiles and cardiac function in streptozotocin-induced diabetic rats. Diabetes. 2005 May; 54(5):1573-80.
    View in: PubMed
    Score: 0.064
  85. Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction. Life Sci. 2005 Apr 08; 76(21):2457-71.
    View in: PubMed
    Score: 0.064
  86. Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum. 2005 Apr; 52(4):1319-24.
    View in: PubMed
    Score: 0.064
  87. Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-glycogen synthase kinase-3 and Akt-Bad.14-3-3 signaling pathways. J Biol Chem. 2005 Mar 04; 280(9):8022-30.
    View in: PubMed
    Score: 0.063
  88. Adrenomedullin gene delivery protects against cerebral ischemic injury by promoting astrocyte migration and survival. Hum Gene Ther. 2004 Dec; 15(12):1243-54.
    View in: PubMed
    Score: 0.063
  89. Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress. Kidney Int. 2004 Aug; 66(2):722-32.
    View in: PubMed
    Score: 0.061
  90. Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension. 2004 Feb; 43(2):452-9.
    View in: PubMed
    Score: 0.059
  91. Adrenomedullin protects against myocardial apoptosis after ischemia/reperfusion through activation of Akt-GSK signaling. Hypertension. 2004 Jan; 43(1):109-16.
    View in: PubMed
    Score: 0.058
  92. Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2003 Oct; 285(4):H1479-88.
    View in: PubMed
    Score: 0.057
  93. Adrenomedullin gene delivery attenuates myocardial infarction and apoptosis after ischemia and reperfusion. Am J Physiol Heart Circ Physiol. 2003 Oct; 285(4):H1506-14.
    View in: PubMed
    Score: 0.057
  94. Structural elements of kallistatin required for inhibition of angiogenesis. Am J Physiol Cell Physiol. 2003 06; 284(6):C1604-13.
    View in: PubMed
    Score: 0.056
  95. Adrenomedullin gene delivery inhibits neointima formation in rat artery after balloon angioplasty. Regul Pept. 2003 Apr 15; 112(1-3):115-20.
    View in: PubMed
    Score: 0.056
  96. Adenovirus-mediated human prostasin gene delivery is linked to increased aldosterone production and hypertension in rats. Am J Physiol Regul Integr Comp Physiol. 2003 Apr; 284(4):R1031-6.
    View in: PubMed
    Score: 0.055
  97. Human endothelial nitric oxide synthase gene delivery promotes angiogenesis in a rat model of hindlimb ischemia. Arterioscler Thromb Vasc Biol. 2002 Aug 01; 22(8):1279-85.
    View in: PubMed
    Score: 0.053
  98. A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness. Am J Pathol. 2001 Nov; 159(5):1797-805.
    View in: PubMed
    Score: 0.051
  99. Adrenomedullin gene delivery attenuates renal damage and cardiac hypertrophy in Goldblatt hypertensive rats. Am J Physiol Renal Physiol. 2001 Jun; 280(6):F964-71.
    View in: PubMed
    Score: 0.049
  100. Identification of a major heparin-binding site in kallistatin. J Biol Chem. 2001 Jan 12; 276(2):1276-84.
    View in: PubMed
    Score: 0.048
  101. A positively charged loop on the surface of kallistatin functions to enhance tissue kallikrein inhibition by acting as a secondary binding site for kallikrein. J Biol Chem. 2000 Dec 22; 275(51):40371-7.
    View in: PubMed
    Score: 0.048
  102. Roles of the P1, P2, and P3 residues in determining inhibitory specificity of kallistatin toward human tissue kallikrein. J Biol Chem. 2000 Dec 08; 275(49):38457-66.
    View in: PubMed
    Score: 0.048
  103. Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats. Hypertension. 2000 Dec; 36(6):995-1001.
    View in: PubMed
    Score: 0.047
  104. Human adrenomedullin gene delivery protects against cardiac hypertrophy, fibrosis, and renal damage in hypertensive dahl salt-sensitive rats. Hum Gene Ther. 2000 Sep 01; 11(13):1817-27.
    View in: PubMed
    Score: 0.047
  105. Bradykinin B(1) receptor mediates inhibition of neointima formation in rat artery after balloon angioplasty. Hypertension. 2000 Sep; 36(3):364-70.
    View in: PubMed
    Score: 0.047
  106. Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. Kidney Int. 2000 Aug; 58(2):730-9.
    View in: PubMed
    Score: 0.046
  107. Reactive-site specificity of human kallistatin toward tissue kallikrein probed by site-directed mutagenesis. Biochim Biophys Acta. 2000 Jun 15; 1479(1-2):237-46.
    View in: PubMed
    Score: 0.046
  108. Kallistatin stimulates vascular smooth muscle cell proliferation and migration in vitro and neointima formation in balloon-injured rat artery. Circ Res. 2000 Mar 03; 86(4):418-24.
    View in: PubMed
    Score: 0.045
  109. Enhanced renal function in bradykinin B(2) receptor transgenic mice. Am J Physiol Renal Physiol. 2000 Mar; 278(3):F484-91.
    View in: PubMed
    Score: 0.045
  110. Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension. 2000 Jan; 35(1 Pt 1):25-31.
    View in: PubMed
    Score: 0.045
  111. Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats. Immunopharmacology. 1999 Oct 15; 44(1-2):57-65.
    View in: PubMed
    Score: 0.044
  112. Adenovirus-mediated kallikrein gene transfer inhibits neointima formation via increased production of nitric oxide in rat artery. Immunopharmacology. 1999 Oct 15; 44(1-2):137-43.
    View in: PubMed
    Score: 0.044
  113. Human tissue kallikrein attenuates hypertension and secretes into circulation and urine after intramuscular gene delivery in hypertensive rats. Clin Exp Hypertens. 1999 Oct; 21(7):1145-60.
    View in: PubMed
    Score: 0.044
  114. Adenovirus-mediated kallikrein gene delivery reduces aortic thickening and stroke-induced death rate in Dahl salt-sensitive rats. Stroke. 1999 Sep; 30(9):1925-31; discussion 1931-2.
    View in: PubMed
    Score: 0.044
  115. Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty. Hypertension. 1999 Aug; 34(2):164-70.
    View in: PubMed
    Score: 0.043
  116. Atrial natriuretic peptide gene delivery attenuates gentamycin-induced nephrotoxicity in rats. Nephrol Dial Transplant. 1999 Jun; 14(6):1376-84.
    View in: PubMed
    Score: 0.043
  117. Potassium supplement upregulates the expression of renal kallikrein and bradykinin B2 receptor in SHR. Am J Physiol. 1999 03; 276(3):F476-84.
    View in: PubMed
    Score: 0.042
  118. Localization and expression of tissue kallikrein and kallistatin in human blood vessels. J Histochem Cytochem. 1999 Feb; 47(2):221-8.
    View in: PubMed
    Score: 0.042
  119. Atrial natriuretic peptide gene delivery reduces stroke-induced mortality rate in Dahl salt-sensitive rats. Hypertension. 1999 Jan; 33(1 Pt 2):219-24.
    View in: PubMed
    Score: 0.042
  120. Molecular cloning and expression of rat bradykinin B1 receptor. Biochim Biophys Acta. 1998 Nov 08; 1442(2-3):177-85.
    View in: PubMed
    Score: 0.041
  121. Cellular localization of kallistatin and tissue kallikrein in human pancreas and salivary glands. Histochem Cell Biol. 1998 Nov; 110(5):477-84.
    View in: PubMed
    Score: 0.041
  122. Atrial natriuretic peptide gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in salt-sensitive rats. Hum Gene Ther. 1998 Jul 01; 9(10):1429-38.
    View in: PubMed
    Score: 0.040
  123. Human kallikrein gene delivery protects against gentamycin-induced nephrotoxicity in rats. Kidney Int. 1998 May; 53(5):1305-13.
    View in: PubMed
    Score: 0.040
  124. Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension. 1998 May; 31(5):1104-10.
    View in: PubMed
    Score: 0.040
  125. Central delivery of human tissue kallikrein gene reduces blood pressure in hypertensive rats. Biochem Biophys Res Commun. 1998 Mar 17; 244(2):449-54.
    View in: PubMed
    Score: 0.039
  126. Transcription factor nuclear factor kappaB regulates the inducible expression of the human B1 receptor gene in inflammation. J Biol Chem. 1998 Jan 30; 273(5):2784-91.
    View in: PubMed
    Score: 0.039
  127. Adrenomedullin gene delivery reduces blood pressure in spontaneously hypertensive rats. Hypertens Res. 1997 Dec; 20(4):269-77.
    View in: PubMed
    Score: 0.039
  128. Effect of cyclosporin A on the expression of tissue kallikrein, kininogen, and bradykinin receptor in rat. Am J Physiol. 1997 11; 273(5):F783-9.
    View in: PubMed
    Score: 0.038
  129. Gene therapy in hypertension: adenovirus-mediated kallikrein gene delivery in hypertensive rats. Hum Gene Ther. 1997 Oct 10; 8(15):1753-61.
    View in: PubMed
    Score: 0.038
  130. Molecular cloning and expression of rat kallistatin gene. Biochim Biophys Acta. 1997 Sep 12; 1353(3):277-86.
    View in: PubMed
    Score: 0.038
  131. Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. Hypertension. 1997 Sep; 30(3 Pt 1):307-13.
    View in: PubMed
    Score: 0.038
  132. Tissue-specific expression and promoter analyses of the human tissue kallikrein gene in transgenic mice. Biochem J. 1997 Jul 01; 325 ( Pt 1):111-6.
    View in: PubMed
    Score: 0.037
  133. Expression of human tissue kallikrein in rat salivary glands and its secretion into circulation following adenovirus-mediated gene transfer. Immunopharmacology. 1997 Jun; 36(2-3):221-7.
    View in: PubMed
    Score: 0.037
  134. DNA polymorphisms in the 5'-flanking region of the human tissue kallikrein gene. Hum Genet. 1997 Jun; 99(6):727-34.
    View in: PubMed
    Score: 0.037
  135. Plasma kallistatin in critically ill patients with severe sepsis and septic shock. PLoS One. 2017; 12(5):e0178387.
    View in: PubMed
    Score: 0.037
  136. Expression and localization of human kallistatin in rat submandibular gland after intracapsular gene injection. Biochem Biophys Res Commun. 1997 Feb 13; 231(2):494-8.
    View in: PubMed
    Score: 0.036
  137. Adenovirus-mediated delivery of human kallistatin gene reduces blood pressure of spontaneously hypertensive rats. Hum Gene Ther. 1997 Feb 10; 8(3):341-7.
    View in: PubMed
    Score: 0.036
  138. Hypotension in transgenic mice overexpressing human bradykinin B2 receptor. Hypertension. 1997 Jan; 29(1 Pt 2):488-93.
    View in: PubMed
    Score: 0.036
  139. Beneficial effects of kallikrein-binding protein in transgenic mice during endotoxic shock. Life Sci. 1997; 60(17):1431-5.
    View in: PubMed
    Score: 0.036
  140. Tissue kallikrein-binding protein reduces blood pressure in transgenic mice. J Biol Chem. 1996 Nov 01; 271(44):27590-4.
    View in: PubMed
    Score: 0.036
  141. High level of circulating human tissue kallikrein induces hypotension in a transgenic mouse model. Clin Exp Hypertens. 1996 Nov; 18(8):975-93.
    View in: PubMed
    Score: 0.036
  142. Kallistatin in human ocular tissues: reduced levels in vitreous fluids from patients with diabetic retinopathy. Curr Eye Res. 1996 Nov; 15(11):1117-23.
    View in: PubMed
    Score: 0.036
  143. High-salt diet upregulates kininogen and downregulates tissue kallikrein expression in Dahl-SS and SHR rats. Am J Physiol. 1996 Oct; 271(4 Pt 2):F824-30.
    View in: PubMed
    Score: 0.036
  144. Expression and cellular localization of tissue kallikrein-kinin system in human adrenal gland. Am J Physiol. 1996 Sep; 271(3 Pt 2):F709-16.
    View in: PubMed
    Score: 0.035
  145. Identification and characterization of two promoters of rat kallikrein-binding protein gene. Biochim Biophys Acta. 1996 Jul 17; 1307(3):285-93.
    View in: PubMed
    Score: 0.035
  146. Differential regulation of kallikrein, kininogen, and kallikrein-binding protein in arterial hypertensive rats. Am J Physiol. 1996 Jul; 271(1 Pt 2):F78-86.
    View in: PubMed
    Score: 0.035
  147. Expression and cellular localization of the kallikrein-kinin system in human ocular tissues. Exp Eye Res. 1996 Jul; 63(1):19-26.
    View in: PubMed
    Score: 0.035
  148. Cellular localization of bradykinin B1 receptor mRNA in the human kidney. Immunopharmacology. 1996 Jun; 33(1-3):151-6.
    View in: PubMed
    Score: 0.035
  149. Cellular localization of low-molecular-weight kininogen and bradykinin B2 receptor mRNAs in human kidney. Am J Physiol. 1996 Jun; 270(6 Pt 2):F919-26.
    View in: PubMed
    Score: 0.035
  150. High level expression of human tissue kallikrein in the circulation induces hypotension in transgenic mice. Immunopharmacology. 1996 May; 32(1-3):105-7.
    View in: PubMed
    Score: 0.035
  151. Structure and chromosomal localization of the human prostasin (PRSS8) gene. Genomics. 1996 Mar 15; 32(3):334-40.
    View in: PubMed
    Score: 0.034
  152. Genomic DNA sequence, expression, and chromosomal localization of the human B1 bradykinin receptor gene BDKRB1. Genomics. 1996 Jan 01; 31(1):51-7.
    View in: PubMed
    Score: 0.034
  153. Regulatory elements in the promoter region of the renal kallikrein gene in normotensive vs hypertensive rats. Biochem Biophys Res Commun. 1995 Dec 05; 217(1):113-22.
    View in: PubMed
    Score: 0.034
  154. Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats. Hypertension. 1995 Dec; 26(6 Pt 1):847-53.
    View in: PubMed
    Score: 0.034
  155. Cellular localization of tissue kallikrein and kallistatin mRNAs in human kidney. Kidney Int. 1995 Sep; 48(3):690-7.
    View in: PubMed
    Score: 0.033
  156. Kallistatin protects against sepsis-related acute lung injury via inhibiting inflammation and apoptosis. Sci Rep. 2015 Jul 22; 5:12463.
    View in: PubMed
    Score: 0.033
  157. Kallistatin ameliorates influenza virus pathogenesis by inhibition of kallikrein-related peptidase 1-mediated cleavage of viral hemagglutinin. Antimicrob Agents Chemother. 2015 Sep; 59(9):5619-30.
    View in: PubMed
    Score: 0.033
  158. Molecular cloning, tissue-specific expression, and cellular localization of human prostasin mRNA. J Biol Chem. 1995 Jun 02; 270(22):13483-9.
    View in: PubMed
    Score: 0.032
  159. Molecular cloning, purification and in situ localization of human colon kallikrein. Biochem J. 1995 Apr 15; 307 ( Pt 2):481-6.
    View in: PubMed
    Score: 0.032
  160. Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J Clin Invest. 1995 Apr; 95(4):1710-6.
    View in: PubMed
    Score: 0.032
  161. Muscle delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hypertension. 1995 Apr; 25(4 Pt 2):715-9.
    View in: PubMed
    Score: 0.032
  162. Intramuscular delivery of rat kallikrein-binding protein gene reverses hypotension in transgenic mice expressing human tissue kallikrein. J Biol Chem. 1995 Jan 06; 270(1):451-5.
    View in: PubMed
    Score: 0.032
  163. Cloning, sequence analysis and expression of the gene encoding the mouse bradykinin B2 receptor. Gene. 1994 Nov 18; 149(2):283-8.
    View in: PubMed
    Score: 0.031
  164. Histopathology of lymphatic tissues in transgenic mice expressing human tissue kallikrein gene. Lab Invest. 1994 Nov; 71(5):680-7.
    View in: PubMed
    Score: 0.031
  165. Structure and chromosomal localization of the gene (BDKRB2) encoding human bradykinin B2 receptor. Genomics. 1994 Sep 15; 23(2):362-9.
    View in: PubMed
    Score: 0.031
  166. Molecular cloning, sequence analysis, and chromosomal localization of the human protease inhibitor 4 (kallistatin) gene (PI4). Genomics. 1994 Sep 15; 23(2):370-8.
    View in: PubMed
    Score: 0.031
  167. Molecular cloning and sequence analysis of rat bradykinin B2 receptor gene. Biochim Biophys Acta. 1994 Sep 13; 1219(1):171-4.
    View in: PubMed
    Score: 0.031
  168. Molecular cloning and characterization of a novel kallikrein transcript in colon and its distribution in human tissues. Braz J Med Biol Res. 1994 Aug; 27(8):1829-38.
    View in: PubMed
    Score: 0.031
  169. Prostasin is a novel human serine proteinase from seminal fluid. Purification, tissue distribution, and localization in prostate gland. J Biol Chem. 1994 Jul 22; 269(29):18843-8.
    View in: PubMed
    Score: 0.031
  170. Human tissue kallikrein induces hypotension in transgenic mice. Hypertension. 1994 Feb; 23(2):236-43.
    View in: PubMed
    Score: 0.030
  171. Kallistatin: a novel human serine proteinase inhibitor. Molecular cloning, tissue distribution, and expression in Escherichia coli. J Biol Chem. 1993 Nov 15; 268(32):24498-505.
    View in: PubMed
    Score: 0.029
  172. Kallistatin modulates immune cells and confers anti-inflammatory response to protect mice from group A streptococcal infection. Antimicrob Agents Chemother. 2013 Nov; 57(11):5366-72.
    View in: PubMed
    Score: 0.029
  173. Expression and characterization of rat kallikrein-binding protein in Escherichia coli. Biochem J. 1993 Jun 15; 292 ( Pt 3):825-32.
    View in: PubMed
    Score: 0.028
  174. Plasma kallistatin levels in patients with severe community-acquired pneumonia. Crit Care. 2013 Feb 08; 17(1):R27.
    View in: PubMed
    Score: 0.028
  175. Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. J Biol Chem. 1992 Dec 25; 267(36):25873-80.
    View in: PubMed
    Score: 0.027
  176. Molecular cloning and characterization of rKlk10, a cDNA encoding T-kininogenase from rat submandibular gland and kidney. Biochemistry. 1992 Nov 10; 31(44):10922-8.
    View in: PubMed
    Score: 0.027
  177. Specificity determinants of rat tissue kallikrein probed by site-directed mutagenesis. Protein Eng. 1992 Sep; 5(6):569-75.
    View in: PubMed
    Score: 0.027
  178. Biochemical characterization and substrate specificity of rat prostate kallikrein (S3): comparison with tissue kallikrein, tonin and T-kininogenase. Biochim Biophys Acta. 1992 Jun 24; 1121(3):309-16.
    View in: PubMed
    Score: 0.026
  179. Differential regulation of kininogen gene expression by estrogen and progesterone in vivo. Biochim Biophys Acta. 1992 Jun 15; 1131(2):145-51.
    View in: PubMed
    Score: 0.026
  180. In vivo catabolism of human kallikrein-binding protein and its complex with tissue kallikrein. J Lab Clin Med. 1992 May; 119(5):514-21.
    View in: PubMed
    Score: 0.026
  181. Evolution of the kallikrein gene family. Agents Actions Suppl. 1992; 38 ( Pt 1):26-33.
    View in: PubMed
    Score: 0.026
  182. Comparative studies on P2 specificity of wild-type rat tissue kallikrein, Y99H:W215G mutant and tonin. Agents Actions Suppl. 1992; 38 ( Pt 1):59-65.
    View in: PubMed
    Score: 0.026
  183. Localization of kallikrein gene family proteases in rat tissues. Agents Actions Suppl. 1992; 38 ( Pt 1):595-602.
    View in: PubMed
    Score: 0.026
  184. Molecular cloning and sequence analysis of the mouse kallikrein-binding protein gene. Biochim Biophys Acta. 1991 Dec 02; 1129(1):127-30.
    View in: PubMed
    Score: 0.025
  185. Molecular cloning and analysis of the rat kallikrein-binding protein gene. J Biol Chem. 1991 Aug 25; 266(24):16029-36.
    View in: PubMed
    Score: 0.025
  186. Purification and characterization of recombinant tissue kallikrein from Escherichia coli and yeast. Biochem J. 1991 May 15; 276 ( Pt 1):63-71.
    View in: PubMed
    Score: 0.024
  187. Inhibition of experimental lung metastasis by systemic lentiviral delivery of kallistatin. BMC Cancer. 2010 May 31; 10:245.
    View in: PubMed
    Score: 0.023
  188. Differential interactions of human kallikrein-binding protein and alpha 1-antitrypsin with human tissue kallikrein. Biochem J. 1990 Apr 01; 267(1):79-84.
    View in: PubMed
    Score: 0.023
  189. Molecular cloning and primary structure of rat alpha 1-antitrypsin. Biochemistry. 1990 Jan 16; 29(2):323-9.
    View in: PubMed
    Score: 0.022
  190. Kallikrein multigene families and the regulation of their expression. J Cardiovasc Pharmacol. 1990; 15 Suppl 6:S7-16.
    View in: PubMed
    Score: 0.022
  191. Co-localization of a kallikrein-like serine protease (arginine esterase A) and atrial natriuretic peptide in rat atrium. J Histochem Cytochem. 1989 Dec; 37(12):1913-7.
    View in: PubMed
    Score: 0.022
  192. Restriction fragment length polymorphisms mapped in spontaneously hypertensive rats using kallikrein probes. J Hypertens. 1989 Nov; 7(11):865-71.
    View in: PubMed
    Score: 0.022
  193. Sex dimorphism and inflammatory regulation of T-kininogen and T-kininogenase. Biochim Biophys Acta. 1989 Jun 27; 991(3):477-83.
    View in: PubMed
    Score: 0.021
  194. Characterization of genes encoding rat tonin and a kallikrein-like serine protease. Biochemistry. 1989 Jun 27; 28(13):5334-43.
    View in: PubMed
    Score: 0.021
  195. Renal kallikrein mRNA localization by in situ hybridization. Kidney Int. 1989 Jun; 35(6):1324-9.
    View in: PubMed
    Score: 0.021
  196. Adenovirus-mediated kallistatin gene transfer ameliorates disease progression in a rat model of osteoarthritis induced by anterior cruciate ligament transection. Hum Gene Ther. 2009 Feb; 20(2):147-58.
    View in: PubMed
    Score: 0.021
  197. Enhanced specificity in immunoscreening of expression cDNA clones using radiolabeled antigen overlay. Biotechniques. 1989 Jan; 7(1):68-72.
    View in: PubMed
    Score: 0.021
  198. Human kallistatin, a new tissue kallikrein-binding protein: purification and characterization. Adv Exp Med Biol. 1989; 247B:1-8.
    View in: PubMed
    Score: 0.021
  199. Comparison of the distribution of tissue kallikrein and esterase A, a kallikrein-like enzyme, in rat kidney using specific monoclonal antibodies. J Histochem Cytochem. 1988 Oct; 36(10):1251-4.
    View in: PubMed
    Score: 0.020
  200. Molecular cloning and characterization of two rat renal kallikrein genes. Biochemistry. 1988 Sep 20; 27(19):7189-96.
    View in: PubMed
    Score: 0.020
  201. Immunocytochemical localization of a kallikrein-like serine protease (esterase A) in rat salivary glands. Anat Rec. 1988 May; 221(1):475-81.
    View in: PubMed
    Score: 0.020
  202. Identification of latent tissue kallikrein, prolactin and growth hormone secretion in GH3 pituitary cells using modified radioimmunoassays. Mol Cell Endocrinol. 1988 Jan; 55(1):21-31.
    View in: PubMed
    Score: 0.019
  203. Identification of tonin in brain and exocrine tissues and in the cell-free translation products encoded by the mRNA of these tissues. Biochem J. 1987 Dec 01; 248(2):477-81.
    View in: PubMed
    Score: 0.019
  204. Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5'-monophosphate-activated protein kinase signaling pathways. Endocrinology. 2007 May; 148(5):2016-26.
    View in: PubMed
    Score: 0.018
  205. Prostasin attenuates inducible nitric oxide synthase expression in lipopolysaccharide-induced urinary bladder inflammation. Am J Physiol Renal Physiol. 2006 Sep; 291(3):F567-77.
    View in: PubMed
    Score: 0.017
  206. Encapsulated transgene cells attenuate hypertension, cardiac hypertrophy and enhance renal function in Goldblatt hypertensive rats. J Gene Med. 2004 Jul; 6(7):786-97.
    View in: PubMed
    Score: 0.015
  207. Circulating tissue kallikrein levels correlate with severity of carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2004 Jun; 24(6):1104-10.
    View in: PubMed
    Score: 0.015
  208. Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats. Hypertension. 2003 Nov; 42(5):1026-33.
    View in: PubMed
    Score: 0.014
  209. Reversal of angiogenic growth factor upregulation by revascularization of lower limb ischemia. Circulation. 2002 Jan 01; 105(1):67-72.
    View in: PubMed
    Score: 0.013
  210. Kallikrein-binding protein is induced by growth hormone in the dwarf rat. FASEB J. 1999 Oct; 13(13):1839-44.
    View in: PubMed
    Score: 0.011
  211. Kallikrein-binding protein levels are reduced in the retinas of streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci. 1997 Mar; 38(3):658-64.
    View in: PubMed
    Score: 0.009
  212. Effects of diabetes and insulin on expression of kallikrein and renin genes in the kidney. Kidney Int. 1992 Apr; 41(4):789-95.
    View in: PubMed
    Score: 0.007
  213. Identification and characterization of a tissue kallikrein in rat skeletal muscles. Biochem J. 1987 May 01; 243(3):773-8.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.